# Amylyx Pharmaceuticals Inc. (AMLX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $29.20, market value $3.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Amylyx Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 13.6×**. The shares trade at 13.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -47.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: -43.5%**. Each dollar of assets produces -43.5% of profit.

## Growth
- **Revenue growth (1 yr): -100.0%** (3-yr -100.0%/yr). Revenue fell 100.0% over the last year.
- **EPS growth (1 yr): 65.5%**. Earnings per share rose 65.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 14.27** (quick 14.27). Current assets cover the next year's liabilities 14.27 times.
- **Altman Z-score: 81.15**. A Z-score of 81.15 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Amylyx Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (11 analysts). 11 analysts cover Amylyx Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $42.64 (+46% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 101.3%** (YTD 132.1%, 3-mo 39.0%). The shares are up 101.3% over twelve months including dividends.
- **From 52-week high: -29.0%** (169.6% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.84** (volatility 87%). Beta of 0.84 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AMLX · Page: https://foliofundamentals.com/stocks/amlx

Not investment advice.